Global Leader in Oral Delivery of Therapeutic Proteins

We are a clinical stage, global company, focused on high unmet clinical needs where oral delivery of a protein therapy can significantly improve the standard of care


Entera is Daring Courageous Fierce

We are developing first-in-class, daily tablet protein and peptide replacement therapies, designed for patients to live healthier and injection-free, as they manage their chronic diseases. Our goal is for our small, oral protein tablets to change treatment outcomes for patients globally.

Therapeutic Areas


Osteoporosis is a disease characterized by low bone mass and structural deterioration of bone tissue, which leads to greater fragility and an increase in fracture risk.

Hypoparathyroidism is a rare condition in which the parathyroid glands fail to produce sufficient amounts of parathyroid hormone or the parathyroid hormone produced lacks biologic activity.


Press Releases

Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

Entera’s Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics


Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613’s Potential Impact

Thank You

Message Sent!

We will get back to you soon